Related Experiment Video
Updated: Mar 20, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth
Shi Chen1, Qian Wang2, Xian-Mei Zhou2
1Department of Respiratory Disease, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Abstract:
MicroRNA (miR)‑27b has been reported to partici-pate in regulating the activity of non‑small cell lung carcinoma (NSCLC) cells. Additionally, when downregulated in NSCLC it promotes resistance to docetaxel; however, the underlying molecular mechanism remains largely unknown. Using reverse transcription‑quantitative polymerase chain reaction, the present study determined that the expression of miR‑27b was significantly reduced in NSCLC cells that were resistant to docetaxel. In addition, epidermal growth factor receptor (EGFR) was identified as a possible target of miR‑27b by searching the online miRNA database, TargetScan. A luciferase assay further validated EGFR as an effective target gene of miR‑27b. In addition, it was determined that in tumor tissue samples resistant to docetaxel miR‑27b was significantly downregulated, whilst EGFR was significantly upregulated. miR‑27b negatively regulated the expression of EGFR. This was evident as the transfection of miR‑27b mimics led to downregulation of the expression levels of EGFR, whilst miR‑27b inhibitors upregulated the expression levels of EGFR. Furthermore, it was demonstrated that the transfection of miR‑27b mimics significantly suppressed the apoptosis and promote the viability of A549 human lung carcinoma cells. In line with this, the introduction of miR‑27b inhibitors significantly induced apoptosis and inhibited the proliferation of A549 cells. These results indicate that miR‑27b may promote NSCLC cell viability and enhance resistance to docetaxel treatment through direct inhibition of EGFR expression. Additionally, miR‑27b may become a promising molecular target for improving the effectiveness of chemotherapy with docetaxel.
Insights
MicroRNA-27b (miR-27b) downregulation in non-small cell lung carcinoma (NSCLC) enhances docetaxel resistance by upregulating epidermal growth factor receptor (EGFR). Restoring miR-27b may improve chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA-27b (miR-27b) plays a role in non-small cell lung carcinoma (NSCLC) cell activity.
- Downregulation of miR-27b in NSCLC is linked to docetaxel resistance, but the mechanism is unclear.
Purpose of the Study:
- To investigate the molecular mechanism by which miR-27b affects docetaxel resistance in NSCLC.
- To identify the target gene of miR-27b involved in this process.
Main Methods:
- Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to measure miR-27b expression.
- Bioinformatic analysis (TargetScan) and luciferase assay to identify and validate miR-27b targets.
- Transfection of miR-27b mimics and inhibitors in NSCLC cells (A549) to assess effects on apoptosis and proliferation.
Main Results:
- miR-27b expression was significantly reduced in docetaxel-resistant NSCLC cells and tumor tissues.
- Epidermal growth factor receptor (EGFR) was validated as a direct target of miR-27b.
- miR-27b negatively regulated EGFR expression; miR-27b mimics decreased EGFR, while inhibitors increased it.
- miR-27b mimics promoted NSCLC cell viability and suppressed apoptosis, whereas inhibitors induced apoptosis and inhibited proliferation.
Conclusions:
- miR-27b promotes NSCLC cell viability and docetaxel resistance by directly inhibiting EGFR expression.
- miR-27b represents a potential molecular target for enhancing the efficacy of docetaxel chemotherapy in NSCLC.
Related Concept Videos
MicroRNAs
MicroRNAs
Drugs that Stabilize Microtubules

